RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cue Biopharma Stock

Cue Biopharma ROCE 2025

Cue Biopharma ROCE

-2.38

Ticker

CUE

ISIN

US22978P1066

WKN

A2JAT5

In 2025, Cue Biopharma's return on capital employed (ROCE) was -2.38, a 69.54% increase from the -1.4 ROCE in the previous year.

Cue Biopharma Aktienanalyse

What does Cue Biopharma do?

Cue Biopharma Inc is a biotechnology company focused on the development of novel immune-competent molecules for cancer therapy and immune system strengthening. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts. The history of Cue Biopharma Inc began with the founding of the company by three leading scientists who combined their expertise in biology, chemistry, and drug design to develop novel and effective cancer immunotherapies. The company aimed to develop these new therapies with the precision of molecular interactions that are crucial for immune system control. Cue Biopharma Inc has a unique business model based on its proprietary CueMol technology platform, which enables the company to gain insightful understanding of molecular interactions in the immune system. By combining bioinformatics, artificial intelligence, and experimental technologies, CueMol is able to model the complex interplay of proteins, cells, and tissues in the immune system. The various divisions of Cue Biopharma Inc can be divided into three main areas: oncology, autoimmune diseases, and infectious diseases. In the field of oncology, the company has a pipeline of products including CB-010, CB-020, and CB-030, targeting different types of tumors. These therapeutics work by blocking protein-protein interactions that enable cancer cells to escape immune surveillance, thus improving the ability of the immune system to recognize and fight the tumor. In the field of autoimmune diseases, Cue Biopharma Inc has made significant progress in the development of CB-110, a therapeutic for the treatment of lupus. CB-110 works by regulating T cells, leading to a reduction in the inflammation that causes lupus symptoms. In the field of infectious diseases, Cue Biopharma Inc has played a valuable role in the development of COVID-19 therapeutics. In 2020, the company began developing CB-001, a drug targeting the SARS-CoV-2 virus. CueMol enabled the company to quickly understand the molecular interactions of the virus and develop CB-001 by disrupting these interactions. Cue Biopharma Inc has entered into several partnerships with leading pharmaceutical companies. In 2019, the company collaborated with Merck & Co. to further develop its CueMol platform and develop novel cancer immunotherapies. In 2020, the company worked with the Sheba Medical Center to test the efficacy of CB-001 in COVID-19 patients. Overall, Cue Biopharma Inc is a promising biotechnology company with the ability to develop novel immunotherapeutic drugs for the treatment of cancer, autoimmune diseases, and infectious diseases through the use of innovative technologies such as CueMol. With its partnerships, pipeline of therapeutics, and advanced technologies, Cue Biopharma Inc is poised to play a significant role in the biotechnology industry in the coming years. Cue Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Cue Biopharma's Return on Capital Employed (ROCE)

Cue Biopharma's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Cue Biopharma's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Cue Biopharma's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Cue Biopharma’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Cue Biopharma stock

What is the ROCE (Return on Capital Employed) of Cue Biopharma this year?

The ROCE of Cue Biopharma is -2.38 undefined this year.

How has the ROCE (Return on Capital Employed) of Cue Biopharma developed compared to the previous year?

The ROCE of Cue Biopharma has increased by 69.54% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Cue Biopharma?

A high Return on Capital Employed (ROCE) indicates that Cue Biopharma has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Cue Biopharma?

A low ROCE (Return on Capital Employed) can indicate that Cue Biopharma has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Cue Biopharma impact the company?

An increase in the ROCE of Cue Biopharma can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Cue Biopharma affect the company?

A decrease in ROCE of Cue Biopharma can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Cue Biopharma?

Some factors that can affect Cue Biopharma's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Cue Biopharma so important for investors?

The ROCE of Cue Biopharma is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Cue Biopharma take to improve the ROCE?

To improve the ROCE, Cue Biopharma can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Cue Biopharma pay?

Over the past 12 months, Cue Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cue Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Cue Biopharma?

The current dividend yield of Cue Biopharma is .

When does Cue Biopharma pay dividends?

Cue Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cue Biopharma?

Cue Biopharma paid dividends every year for the past 0 years.

What is the dividend of Cue Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cue Biopharma located?

Cue Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cue Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cue Biopharma from 7/24/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/24/2025.

When did Cue Biopharma pay the last dividend?

The last dividend was paid out on 7/24/2025.

What was the dividend of Cue Biopharma in the year 2024?

In the year 2024, Cue Biopharma distributed 0 USD as dividends.

In which currency does Cue Biopharma pay out the dividend?

The dividends of Cue Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Cue Biopharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Cue Biopharma

Our stock analysis for Cue Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cue Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.